Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Diabetes, Obesity and Metabolism

Volumn 20, Issue 6, 2018, Pages 1453-1460

  Aronson, Ronnie ^a   Frias, Juan ^b   Goldman, Allison ^c   Darekar, Amanda ^d   Lauring, Brett ^e   Terra, Steven G ^c  

^a LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ertugliflozin; monotherapy; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN;

ACUTE PANCREATITIS; ADULT; ARTICLE; BODY WEIGHT LOSS; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; EXERCISE; FUNGAL GENITAL INFECTION; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HAND FRACTURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POLYURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VAGINA CANDIDIASIS; VAGINA MYCOSIS; ADMINISTRATION AND DOSAGE; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECT; FEMALE; KINESIOTHERAPY; MALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; EXERCISE THERAPY; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 85046796886     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13251     Document Type: Article

References (17)

1. Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep. 2016;16:92.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
3. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591-598.
4. Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805-808.
5. Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520-529.
6. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20:530-540.
7. Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20:1111–1120.
8. Terra SG, Focht K, Davies M, et al. Phase III efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721-728.
9. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post design. Sankhya: Indian J Stat B. 2000;62:134-148.
10. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
11. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551-559.
12. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890-898.
13. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35:446-454.
14. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446-456.
15. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.
16. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109-1119.
17. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of phar-macologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373-381.